<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074303</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202101959</org_study_id>
    <nct_id>NCT05074303</nct_id>
  </id_info>
  <brief_title>Beta-glucan and Immune Response to Influenza Vaccine</brief_title>
  <acronym>M-Unity</acronym>
  <official_title>Yeast-derived Beta-glucan Supplementation on Antibody Response Following Influenza Vaccination: A Randomized, Placebo-controlled Study (M-Unity)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danstar Ferment AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber&#xD;
      supplement isolated from baker's yeast, on immune response to the influenza vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beta-glucans have been shown to enhance the innate and adaptive immune responses in cell&#xD;
      cultures, animal models, and humans, thus adults over the age of 50 years receiving the&#xD;
      influenza vaccination may benefit in terms of their immune response from supplementation with&#xD;
      beta-glucans. This is a 6-week randomized, double-blind, placebo-controlled, 2-arm parallel&#xD;
      study designed to evaluate the adjuvant effect of beta-glucan dietary supplementation during&#xD;
      influenza vaccination. Participants will consume either the beta-glucan or placebo capsules&#xD;
      for 42 days. Participants will complete an online Qualtrics daily questionnaire of&#xD;
      compliance, fatigue, and cold and flu symptoms throughout the 42-day study. Influenza vaccine&#xD;
      will be administered on or about day 14. The Gastrointestinal Symptom Rating Scale (GSRS) and&#xD;
      the Mood and Feelings Questionnaire (MFQ) will be completed at baseline, 2 weeks and 6 weeks.&#xD;
      Blood draws for antibody and cytokine response will be completed at baseline, and on or about&#xD;
      days 14 and 15, and on day 42.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Titer</measure>
    <time_frame>42 days (Day 1, Day 14, Day 15, and day 42)</time_frame>
    <description>Change in influenza-specific antibodies (IgM, IgG influenza A and B) to the influenza vaccine after beta-glucan supplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokine profile</measure>
    <time_frame>42 days (Day 1, Day 14, Day 15, and day 42)</time_frame>
    <description>Change in TNF-α, IL-1β, IL-6, IL-8, MIP-1α and IFN-γ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of influenza and Covid-19</measure>
    <time_frame>42 days</time_frame>
    <description>Self-reported incidence of influenza and Covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>42 days</time_frame>
    <description>Number of subjects with self-reported fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold and flu symptoms</measure>
    <time_frame>42 days</time_frame>
    <description>Number of subjects with cold and flu symptoms using Modified Jackson Criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy Aging</condition>
  <arm_group>
    <arm_group_label>Beta-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg/day beta-glucan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 mg/day cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>All subjects will receive the influenza vaccine.</description>
    <arm_group_label>Beta-glucan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-glucan</intervention_name>
    <description>2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast</description>
    <arm_group_label>Beta-glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 - 250 mg capsules/day of cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult volunteers ≥ 50 years of age.&#xD;
&#xD;
          2. Planning to be vaccinated for influenza&#xD;
&#xD;
          3. Have been immunized for COVID-19&#xD;
&#xD;
          4. Willing and able to provide written informed consent in English.&#xD;
&#xD;
          5. Willing and able to comply with all the study-related procedures, including attending&#xD;
             to study visits for blood draw, taking the influenza vaccine, intake of the study&#xD;
             supplement, and completing study questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Demonstrate an inability to comply with the study-related procedures.&#xD;
&#xD;
          2. Have a history of a severe reaction or hypersensitivity following vaccination with&#xD;
             influenza vaccine, vaccination with any other vaccine containing the same substances,&#xD;
             or intake of the study product.&#xD;
&#xD;
          3. Have an immune system alteration because of an underlying illness (e.g., autoimmune&#xD;
             disease) or immune-suppressing treatment (e.g., steroids (last 30 days); cytotoxic&#xD;
             drugs, medical surgery, or radiation therapy during the 6 months, previous to&#xD;
             enrollment).&#xD;
&#xD;
          4. Be concurrently participating in a clinical trial that, in the judgement of the&#xD;
             investigator, would interfere with the evaluation of the study outcomes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendy J Dahl, PhD</last_name>
    <phone>352-294-3707</phone>
    <email>wdahl@ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Rivero-Mendoza, MS</last_name>
    <phone>352-263-9136</phone>
    <email>ufnutrition@ifas.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Food Science and Human Nutrition Department, University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>beta-glucan; influenza; immunity; antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

